Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2014. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMR) in accordance with the Disclosure and Transparency Rules.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory notification regarding share transactions and does not contain financial performance data.
Material Changes
The filing details specific changes in share interests for two individuals on May 1, 2014, resulting from the exercise of nil-priced options under the GSK Deferred Annual Bonus Plan:
- Sir Andrew Witty: Exercised options over 37,182 and 14,799 shares (granted Feb 24, 2011; vested Feb 24, 2014). Received a net-of-tax value in shares totaling 27,549.
- Mr D S Redfern: Exercised options over 8,837 and 3,518 shares (granted Feb 24, 2011; vested Feb 24, 2014). Received a net-of-tax value in shares totaling 6,548.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of the aforementioned share transactions.
Investor Verification Points
- Verify the total number of shares issued to Sir Andrew Witty (27,549) and Mr D S Redfern (6,548) against the company's cap table.
- Confirm the vesting date of the underlying options (February 24, 2014) and the grant date (February 24, 2011).
- Ensure the transactions were reported in compliance with paragraph 3.1.4R(1)(a) of the Disclosure and Transparency Rules.